Streetbeat News

Regulatory

INCY

Incyte's povorcitinib achieved statistical significance in phase 3 trials for Hidradenitis Suppurativa, supporting its 'Buy' rating. The HS market is projected to grow significantly, and Incyte may benefit from expanded approval discussions for OPZELURA.

Portfolio Pulse from

March 18, 2025 | 8:00 pm

BTCUSD

Bitcoin's price has declined from $84,500 to $81,300, likely due to a sell-off related to the Federal Open Market Committee's (FOMC) meeting on March 18-19. FOMC meetings often act as market resets, increasing Bitcoin's price volatility.

Portfolio Pulse from

March 18, 2025 | 8:00 pm

BTCUSD

The Bank of Korea has decided not to include Bitcoin in its foreign exchange reserves, citing concerns over its price volatility.

Portfolio Pulse from

March 18, 2025 | 7:00 pm

BBLC

Belle Bonica Luxe Corp. / Blockchain Loyalty Corp. (BBLC) has had its Shell Risk designation removed by OTC Markets, indicating improved operational transparency and business expansion.

Portfolio Pulse from

March 18, 2025 | 7:00 pm

BBLC

Belle Bonica Luxe Corp. / Blockchain Loyalty Corp. (BBLC) has had its Shell Risk designation removed by OTC Markets, indicating improved operational transparency and business expansion.

Portfolio Pulse from

March 18, 2025 | 7:00 pm

NEXT

NextDecade Corporation announced that the U.S. Court of Appeals for the D.C. Circuit revised its judgment, removing the vacatur risk on FERC's order for the Rio Grande LNG Facility, allowing construction to proceed without impact.

Portfolio Pulse from

March 18, 2025 | 6:45 pm

DIS

LULU

The article discusses the impact of tariff policies on US companies, highlighting upcoming shareholder meetings for Lululemon and Disney as key events to watch for insights into consumer trends.

Portfolio Pulse from

March 18, 2025 | 6:45 pm

NEXT

NextDecade Corporation announced that the U.S. Court of Appeals for the D.C. Circuit revised its judgment, removing the vacatur risk on FERC's order for the Rio Grande LNG Facility, allowing construction to proceed without impact.

Portfolio Pulse from

March 18, 2025 | 6:45 pm

MDT

The FDA has classified the recall of Medtronic's embolization device as 'most serious' after reports of four patient deaths.

Portfolio Pulse from

March 18, 2025 | 6:30 pm